Biotech Values

[DewDiligence]

(OCRX)—Bloomberg piece on HPTX buyout vig is somewhat bullish for OCRX:

http://www.bloomberg.com/news/articles/2015-03-27/hyperion-could-be-next-pharma-target-with-orphan-drugs-real-m-a

Hyperion Therapeutics Inc. could be the next [buyout] target in what’s already been a busy year for deals in the drug industry.

…Hyperion is preparing to start a phase 3 trial to test whether its ammonia-scavenger drug Ravicti can also treat hepatic encephalopathy, a neurological condition that affects patients with liver cirrhosis. Salix Pharmaceuticals Ltd.’s Xifaxan can be used to treat the same ailment so Valeant, which struck a deal for Salix this month, could go after Hyperion as well, said Yang of Brean Capital. Endo International Plc, which lost out in the bidding for Salix, could also be interested…

As previously noted (#msg-111690701), Xifaxan is not indicated for acute HE. Ravicti won’t be either, if it gets a label expansion for HE (https://www.clinicaltrials.gov/ct2/show/NCT00999167 ).